share_log

Eli Lilly and Co | SC TO-C: Written communication relating to an issuer or third party tender offer

Eli Lilly and Co | SC TO-C: Written communication relating to an issuer or third party tender offer

禮來 | SC TO-C：投標報價書面通信
美股sec公告 ·  07/08 07:17
Moomoo AI 已提取核心訊息
Eli Lilly and Company (Eli Lilly) has announced a definitive agreement to acquire Morphic Holding, Inc., a biopharmaceutical company focused on developing oral integrin therapies for chronic diseases. The acquisition, valued at approximately $3.2 billion, will be conducted through a tender offer of $57 per share in cash, representing a significant premium over Morphic's recent stock prices. The transaction has been unanimously approved by both companies' boards and is expected to close in the third quarter of 2024, subject to customary closing conditions and the tender of a majority of Morphic's outstanding shares. Morphic's lead program, MORF-057, is currently in Phase 2 studies for the treatment of inflammatory bowel disease (IBD) and is a key asset in the acquisition, which aims to expand Lilly's immunology pipeline. The tender offer has not yet commenced, and the acquisition is subject to regulatory approvals and other customary conditions. Both companies have advised their shareholders to read the tender offer materials and the Solicitation/Recommendation Statement carefully once they become available.
Eli Lilly and Company (Eli Lilly) has announced a definitive agreement to acquire Morphic Holding, Inc., a biopharmaceutical company focused on developing oral integrin therapies for chronic diseases. The acquisition, valued at approximately $3.2 billion, will be conducted through a tender offer of $57 per share in cash, representing a significant premium over Morphic's recent stock prices. The transaction has been unanimously approved by both companies' boards and is expected to close in the third quarter of 2024, subject to customary closing conditions and the tender of a majority of Morphic's outstanding shares. Morphic's lead program, MORF-057, is currently in Phase 2 studies for the treatment of inflammatory bowel disease (IBD) and is a key asset in the acquisition, which aims to expand Lilly's immunology pipeline. The tender offer has not yet commenced, and the acquisition is subject to regulatory approvals and other customary conditions. Both companies have advised their shareholders to read the tender offer materials and the Solicitation/Recommendation Statement carefully once they become available.
Eli Lilly公司已宣佈與Morphic Holding, Inc.達成明確協議，後者是一家專注於開發口服整合素治療慢性疾病的生物製藥公司。此次收購價值約32億美元，將通過現金每股57美元的要約收購進行，相對於Morphic最近的股票價格，這是一個顯著的溢價。兩家公司董事會已經一致批准了交易，並預計將在2024年第三季度完成，前提是符合慣例的交易結束條件和Morphic未平倉股票中的大多數發行。 Morphic的主要計劃MORF-057目前正在進行治療炎症性腸病（IBD）的第2階段研究，並且是此次收購的關鍵資產，旨在擴大Lilly的免疫學管道。要約收購尚未開始，收購將取決於監管機構的批准和其他慣例條件。兩家公司建議股東仔細閱讀要約收購材料和“徵集/推薦聲明”一旦它們可用。
Eli Lilly公司已宣佈與Morphic Holding, Inc.達成明確協議，後者是一家專注於開發口服整合素治療慢性疾病的生物製藥公司。此次收購價值約32億美元，將通過現金每股57美元的要約收購進行，相對於Morphic最近的股票價格，這是一個顯著的溢價。兩家公司董事會已經一致批准了交易，並預計將在2024年第三季度完成，前提是符合慣例的交易結束條件和Morphic未平倉股票中的大多數發行。 Morphic的主要計劃MORF-057目前正在進行治療炎症性腸病（IBD）的第2階段研究，並且是此次收購的關鍵資產，旨在擴大Lilly的免疫學管道。要約收購尚未開始，收購將取決於監管機構的批准和其他慣例條件。兩家公司建議股東仔細閱讀要約收購材料和“徵集/推薦聲明”一旦它們可用。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息